Ascent Wealth Partners LLC Reduces Position in Abbott Laboratories $ABT

Ascent Wealth Partners LLC reduced its stake in Abbott Laboratories ( NYSE:ABT – Free Report ) by 29.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,255 shares of the healthcare product maker’s stock after selling 27,145 shares during the quarter. Ascent Wealth Partners LLC’s holdings in Abbott Laboratories were worth $6,700,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Freemont Management S.A. grew its position in Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after acquiring an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at $116,580,000. Thrivent Financial for Lutherans boosted its stake in shares of Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after purchasing an additional 48,286 shares during the period. Net Worth Advisory Group acquired a new stake in Abbott Laboratories during the 4th quarter valued at $1,366,000. Finally, Mn Services Vermogensbeheer B.V. increased its stake in Abbott Laboratories by 2.1% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 671,743 shares of the healthcare product maker’s stock worth $84,163,000 after buying an additional 13,543 shares during the period.

Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories stock opened at $100.71 on Friday. The company has a market cap of $175.41 billion, a PE ratio of 32.59, a P/E/G ratio of 1.73 and a beta of 0.61. The company has a fifty day moving average price of $89.89 and a two-hundred day moving average price of $102.17. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49.

Abbott Laboratories last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The company had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the prior year, the company earned $1.26 earnings per share. The firm’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $0.63. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is presently 70.59%.

In related news, CFO Philip P. Boudreau acquired 2,200 shares of the stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share.